Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06299436 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

HALT-RHF
Start date: September 1, 2024
Phase:
Study type: Observational

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

NCT ID: NCT06299176 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Whole Heart Radiotherapy for End-stage Heart Failure

ESHF-WHRT
Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses. Management focuses on controlling symptoms, correcting precipitants, avoiding triggers, and improving quality-of-life. The combination of recent preclinical and clinical data suggests that localized cardiac RT is relatively safe and has positive conductive and anti-proliferative effects in the "sick" heart. In this Phase 1 study, the investigators aim to assess the feasibility and safety of 5 Gy whole heart radiotherapy in six (6) ESHF participants with limited options for further medical therapy to control their disease. The investigators hypothesize that 5 Gy whole heart radiotherapy can improve LVEF and decrease blood markers of heart failure and inflammation including B-type natriuretic peptide (BNP), C-reactive protein (CRP), and troponins, while also having a very tolerable side effect profile.

NCT ID: NCT06298994 Not yet recruiting - Pain Clinical Trials

Determination of Body Awareness and the Functional Movement in Patients With COPD

Start date: March 8, 2024
Phase:
Study type: Observational

The aim of this study is to investigate body awareness and functional movement in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to healthy controls.

NCT ID: NCT06298825 Not yet recruiting - Clinical trials for Acute Decompensated Heart Failure

S-ADHF:Sarcopenia in Patients With ADHF

S-ADHF
Start date: April 1, 2024
Phase:
Study type: Observational

This is a prospective, multi-center, investigator-initiated observational cohort study. Enrollment with a minimum of of 195 cases each for patients with and without sarcopenia. Each patient is followed up for 6 month, 1 year, 2 years or until the occurrence of death.This study will examine the correlation between sarcopenia and prognosis in different subgroups of patients, and explore the additive effect of different comorbidities and sarcopenia on prognosis in patients with acute decompensated heart failure.

NCT ID: NCT06298383 Not yet recruiting - Clinical trials for Symptomatic Irreversible Pulpitis

The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

Pain is a very important factor in Endodontic treatment, Both intra- and Post-operatively. In case of symptomatic Irreversible pulpitis, a build up of inflammatory mediators makes it very difficult for the operator to reach the desired level of anesthesia in order to deliver a pain free treatment as well as to eliminate or at least reduce post-operative pain incidence and severity. therefore, a number of pre- medications was suggested with variable success rates. Therefore this trial aims at the use of a new category of anti-inflammatory medications which would be less harmful than the standard NSAIDs or steroids.

NCT ID: NCT06298266 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Start date: March 29, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma

NCT ID: NCT06297629 Not yet recruiting - Clinical trials for Allogeneic Stem Cell Transplantation

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Start date: July 31, 2024
Phase: Phase 2
Study type: Interventional

To learn if ASTX727 given alone or in combination with donor lymphocyte infusion (DLI) can help to control certain types of hematological neoplasms (blood-based cancers) after a stem cell transplant.

NCT ID: NCT06297421 Not yet recruiting - Mental Health Issue Clinical Trials

Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults

Start date: August 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Fecal Microbiota Transplantation compared with placebo in the treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) and Mental Health Comorbidity in Young Adults.

NCT ID: NCT06297265 Not yet recruiting - Clinical trials for Anatomic Stage IA Breast Cancer AJCC v8

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This phase II trial evaluates manual lymphatic drainage breast massage for reducing treatment-related side effects in women undergoing radiation therapy after breast conserving surgery for breast cancer that has not spread to other parts of the body (localized). Breast conserving surgery can be an effective treatment option for early stage breast cancer, but it can also be associated with side effects including fluid collection in tissues/swelling (lymphedema), pain, reduced quality of life, and poorer body image. Manual lymphatic drainage is a gentle massage technique used to reduce swelling. It may be a safe and effective way to reduce treatment-related side effects in women receiving radiation therapy after surgery for localized breast cancer.

NCT ID: NCT06297122 Not yet recruiting - Clinical trials for Invasive Group A Beta-Haemolytic Streptococcal Disease

Severe Group A Streptococcus Infections in Paris, France, 2018-2023

IGASI
Start date: March 2024
Phase:
Study type: Observational

Streptococcus pyogenes, commonly referred to as Group A Streptococcus (GAS), has the ability to induce a diverse range of illnesses. In several European countries and the United States, a notable surge in invasive GAS (iGAS) infections has been documented since mid-2022. This sharp increase contrasts with the gradual rise in iGAS incidence observed among children over the past three decades. As demonstrated for several viral infections, the recent upturn in iGAS infections is potentially linked to the relaxation of mitigation measures implemented during the COVID-19 pandemic, such as face mask usage and school closures. Since November 2022, concerns have been raised by French public health authorities regarding the rise in levels of iGAS infections, and an unexpected increase in pediatric severe GAS infections was reported in a French single-center study. However, this study ended in December 2022 and could only explore short-term trends. The Necker - Enfants malades Hospital in Paris, France, represents an excellent opportunity to examine the impact of the COVID-19 pandemic and the associated non-pharmaceutical interventions on the incidence of severe GAS infections, during, and after the pandemic. This study aims to investigate trends of severe GAS infection incidence in children in the Paris area over the course of the COVID-19 pandemic.